Evidence map›Paper›PMID 22155239›Full record

ArticleBiochemical and biophysical research communications2012

Structural basis of anthrax edema factor neutralization by a neutralizing antibody.

Michelle Makiya, Michael Dolan, Liane Agulto, Robert Purcell, Zhaochun Chen

Abstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Designing inhibitors of anthrax toxin.Expert opinion on drug discovery · 2014
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Michelle MakiyaLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States.
Michael Dolan
Liane Agulto
Robert Purcell
Zhaochun Chen
National Institutes of Health · USNational Institute of Allergy and Infectious Diseases · US

Funding

New Approaches To Passive ImmunoprophylaxisZIAAI001016 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI PURCELL, ROBERT H. · 2009 to 2012
$3.5M
NEW APPROACHES TO PASSIVE AND ACTIVE IMMUNOPROPHYLAXISZ01AI000823 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI PURCELL, ROBERT H. · 1998 to 2008
$2.9M
New Approaches To Active ImmunoprophylaxisZIAAI000823 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI PURCELL, ROBERT H. · 2009 to 2012
$2.6M
Intramural NIH HHS Z01 AI000823Intramural NIH HHS Z99 AI999999NIAID NIH HHS Y99 AI999999
6 · The paper itself

Abstract

Fine epitope mapping of EF13D, a highly potent neutralizing monoclonal antibody specific for the anthrax edema factor (EF), was accomplished through random mutagenesis and yeast surface display. A yeast-displayed library of single point mutants of an EF domain III (DIII), comprising amino acids 624-800, was constructed by random mutagenesis and screened for reduced binding to EF13D. With this method, residues Leu 667, Ser 668, Arg 671, and Arg 672 were identified as key residues important for EF13D binding. They form a contiguous patch on a solvent-exposed surface at one end of the four-helix bundle of DIII. Computational protein-protein docking experiments between anEF13D model and a crystal structure of EF indicate that the EF13D heavy chain complementarity-determining region 3 (HCDR3) is deeply buried within a hydrophobic cleft between two helices of DIII and interacts directly with residues Leu 667, Ser 668, Arg 671 and Arg 672, providing an explanation for the high binding affinity. In addition, they show that the HCDR3 binding site overlaps with the binding site of the N-terminal lobe of calmodulin (CaM), an EF enzymatic activator, consistent with a previous finding showing direct competition with CaM that results in neutralization of EF. Identifying the neutralization epitope of EF13D on EF improves our understanding of the neutralization mechanism and has implications for vaccine development.

Indexed as

Amino Acid SequenceAnthrax VaccinesAntibodies, MonoclonalAntibodies, NeutralizingAntibody AffinityAntigens, BacterialBacterial ToxinsEpitope MappingMolecular Sequence DataMutagenesis, Site-DirectedNeutralization TestsProtein Conformationanthrax toxinAnthrax VaccinesAntibodies, MonoclonalAntibodies, NeutralizingAntigens, BacterialBacterial Toxins

Identifiers

PMID22155239
PMCPMC3293246
OpenAlexW2113909458

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.